Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study).
about
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs.Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study.Rehabilitation use in multiple sclerosis: Do illness representations matter?
P2860
Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 March 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glatiramer acetate treatment p ...... nt-centred study (CAIR study).
@en
Glatiramer acetate treatment p ...... eb-based patient-centred study
@nl
type
label
Glatiramer acetate treatment p ...... nt-centred study (CAIR study).
@en
Glatiramer acetate treatment p ...... eb-based patient-centred study
@nl
prefLabel
Glatiramer acetate treatment p ...... nt-centred study (CAIR study).
@en
Glatiramer acetate treatment p ...... eb-based patient-centred study
@nl
P2093
P2860
P921
P1476
Glatiramer acetate treatment p ...... nt-centred study (CAIR study).
@en
P2093
Erwin L Hoogervorst
Peter Joseph Jongen
Rogier Donders
Wim A Lemmens
P2860
P2888
P356
10.1186/S12955-017-0622-Z
P577
2017-03-14T00:00:00Z
P6179
1084251383